StockData
Amneal Pharmaceuticals, Inc. logo

Amneal Pharmaceuticals, Inc. (AMRX) stock

AMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3063% above fair value
$21.12−0.11 (-0.52%)

Close on Nov 17, 2026Market cap $6.74BP/E 43.1Yield –

Amneal Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Amneal Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was $453.92M, up 20.6% year over year. For fiscal 2025 it was $394.10M, up 58.1% from the year before. The highest annual figure on record is $394.10M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$394.10M+58.1%
FY2024Dec 31, 2024$249.33M+22.0%
FY2023Dec 31, 2023$204.37M–
FY2022Dec 31, 2022-$94.93M-162.2%
FY2021Dec 31, 2021$152.72M+67.5%
FY2020Dec 31, 2020$91.16M–
FY2019Dec 31, 2019-$248.68M–
FY2018Dec 31, 2018-$19.67M-108.0%
FY2017Dec 31, 2017$245.10M-14.0%
FY2016Dec 31, 2016$284.88M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$129.77M+16.5%
Q1 FY2026Mar 31, 2026$141.77M+41.3%
Q4 FY2025Dec 31, 2025$112.03M+47.8%
Q3 FY2025Sep 30, 2025$70.34M-20.8%
Q2 FY2025Jun 30, 2025$111.37M+16.7%
Q1 FY2025Mar 31, 2025$100.35M–
Q4 FY2024Dec 31, 2024$75.79M+434.0%
Q3 FY2024Sep 30, 2024$88.81M+17.4%
Q2 FY2024Jun 30, 2024$95.47M+19.2%
Q1 FY2024Mar 31, 2024-$10.75M-131.2%
Q4 FY2023Dec 31, 2023$14.19M-60.6%
Q3 FY2023Sep 30, 2023$75.65M+70.6%
Q2 FY2023Jun 30, 2023$80.08M–
Q1 FY2023Mar 31, 2023$34.45M+47.8%
Q4 FY2022Dec 31, 2022$36.03M+222.4%
Q3 FY2022Sep 30, 2022$44.35M+55.5%
Q2 FY2022Jun 30, 2022-$198.62M-395.9%
Q1 FY2022Mar 31, 2022$23.31M-49.2%
Q4 FY2021Dec 31, 2021$11.18M-44.6%
Q3 FY2021Sep 30, 2021$28.52M+1071.0%
Q2 FY2021Jun 30, 2021$67.12M+524.3%
Q1 FY2021Mar 31, 2021$45.91M-20.6%
Q4 FY2020Dec 31, 2020$20.18M–
Q3 FY2020Sep 30, 2020$2.44M–
Q2 FY2020Jun 30, 2020$10.75M–
Q1 FY2020Mar 31, 2020$57.79M–
Q4 FY2019Dec 31, 2019-$23.14M-199.4%
Q3 FY2019Sep 30, 2019-$112.27M-250.6%
Q2 FY2019Jun 30, 2019-$18.91M–
Q1 FY2019Mar 31, 2019-$94.36M-248.5%
Q4 FY2018Dec 31, 2018$23.28M-70.5%
Q3 FY2018Sep 30, 2018$74.56M-5.3%
Q2 FY2018Jun 30, 2018-$181.06M-505.9%
Q1 FY2018Mar 31, 2018$63.55M–
Q4 FY2017Dec 31, 2017$79.02M–
Q3 FY2017Sep 30, 2017$78.75M–
Q2 FY2017Jun 30, 2017$44.60M–

More Amneal Pharmaceuticals figures

See a number that looks wrong?